Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inventiva ( (IVA) ) has shared an announcement.
On October 14, 2025, Inventiva announced the implementation of a new At-The-Market (ATM) program, filing a shelf registration statement with the SEC to issue and sell ordinary shares in the form of American Depositary Shares (ADS) for up to $100 million. The proceeds are intended to finance the research and development of lanifibranor, working capital requirements, and general corporate purposes. The ATM program allows for sales to eligible investors, with the new shares to be traded on Euronext Paris and Nasdaq. This strategic move aims to strengthen Inventiva’s financial position and support its ongoing clinical trials, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (IVA) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
Inventiva’s overall stock score is primarily impacted by its poor financial performance, with persistent losses and negative cash flows. While there are positive developments in clinical trials and strategic partnerships, these are overshadowed by financial instability and valuation concerns. Technical indicators suggest caution, with potential bearish momentum. The earnings call offers some optimism, but significant challenges remain.
To see Spark’s full report on IVA stock, click here.
More about Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH.
Average Trading Volume: 63,988
Technical Sentiment Signal: Buy
Current Market Cap: $640.8M
For detailed information about IVA stock, go to TipRanks’ Stock Analysis page.